GEORGIA BOARD OF PHARMACY
Board Meeting
2 Peachtree Street, NW, 36th Floor
Atlanta, GA 30303
September 20, 2017
9:00 a.m.

The following Board members were present:
Chris Jones, President
Vicki Arnold
Jim Bracewell
Mike Faulk
Lisa Harris
Laird Miller
Bill Prather *(departed @ 2:54 p.m.)*

Staff present:
Tanja Battle, Executive Director
Dennis Troughton, Director, GDNA
Ronnie Higgins, Deputy Director, GDNA
Margaret Brosh, Special Agent, GDNA
Janet Wray, Senior Assistant Attorney General
Max Changus, Assistant Attorney General
Kimberly Emm, Attorney
Brandi Howell, Business Support Analyst I

Visitors
Patricia Kuban, EUH
Teresa Tatum, DME
Keri Conley, GHA
Chad Madill, Publix
Greg Reybold, GPhA
Mark Martinez, GPhA
Robert Stannard, EUH
TJ Kaplan, JLM
Devin Kreel, CSG
Stephen Snow, EUH
Seneathia Harris
Stephanie Levine
Robert Stitt
Jim Bartling
Howard M. Fambrough
Frances Cullen

Open Session

President Jones established that a quorum was present and called the meeting to order at 9:02 a.m.

President Jones welcomed the visitors.

Approval of Minutes
Jim Bracewell made a motion to approve the Public Session minutes from the August 2, 2017 meeting. Lisa Harris seconded and the Board voted unanimously in favor of the motion.

Lisa Harris made a motion to approve the Executive Session minutes from the August 2, 2017 meeting. Mike Faulk seconded and the Board voted unanimously in favor of the motion.

Bill Prather made a motion to approve the Public Session minutes from the August 9, 2017 Conference Call. Laird Miller seconded and the Board voted unanimously in favor of the motion.

Mike Faulk made a motion to approve the Executive Session minutes from the August 9, 2017 Conference Call. Lisa Harris seconded and the Board voted unanimously in favor of the motion.

Jim Bracewell made a motion to approve the minutes from the September 8, 2017 Emergency Conference Call. Bill Prather seconded and the Board voted unanimously in favor of the motion.

Report of Licenses Issued

Lisa Harris made a motion to ratify the list of licenses issued. Mike Faulk seconded and the Board voted unanimously in favor of the motion.

Petition for Rule Waiver from Aclaris Therapeutics

Mike Faulk made a motion to grant the rule waiver petition. Jim Bracewell seconded and the Board voted unanimously in favor of the motion.

Petition for Rule Waiver from Imprimis NJOF, LLC

Jim Bracewell made a motion to grant the rule waiver petition. Vicki Arnold seconded and the Board voted unanimously in favor of the motion.

Petition for Rule Waiver from Optim Screven Medical Center, PHH003751

Vicki Arnold made a motion to grant the rule waiver petition. Jim Bracewell seconded and the Board voted unanimously in favor of the motion.

Petition for Rule Waiver from Vilvet Pharmaceuticals

Jim Bracewell made a motion to grant the rule waiver petition. Mike Faulk seconded and the Board voted unanimously in favor of the motion.

Correspondence from Dr. Lois Lassiter

The Board considered this correspondence regarding pharmacies not wanting to fill prescriptions because it does not have an NPI number. Bill Prather made a motion to direct staff to respond by stating the Board wishes to thank Dr. Lassiter for her correspondence and to be advised that the Board will contact the Georgia Pharmacy Association to educate pharmacists on this matter. Jim Bracewell seconded and the Board voted unanimously in favor of the motion.

Correspondence from Craig B. Greenfield, Aegis Healthcare Solutions, Inc.

The Board discussed Mr. Greenfield's correspondence at its July meeting regarding two pharmacies related through common ownership. At that time the Board requested additional information. Mr. Greenfield has now provided additional information for the Board's consideration. Lisa Harris made a motion to direct staff to respond by stating both pharmacies would need to be licensed in Georgia and in compliance with the laws and rules of their home state. Laird Miller seconded and the Board voted unanimously in favor of the motion.

Correspondence from Tatyana Livitina

The Board considered this correspondence requesting clarification regarding whether FDA e-CFR Title 21, §205.3 is restricted in Georgia. Bill Prather made a motion to table this matter until the Board's October meeting to allow additional time to review. Lisa Harris seconded and the Board voted unanimously in favor of the motion.

Correspondence from Angela Wampler

The Board considered this correspondence regarding transfers of controlled substances CIII-V between pharmacies. Laird Miller made a motion to direct staff to respond by stating that federal rule prohibits transfer of received, but never filled controlled substance prescriptions, except for in the case of electronic to electronic prescriptions. Bill Prather seconded and the Board voted unanimously in favor of the motion.

Correspondence from Michelle Pasqualetti

The Board considered this correspondence regarding whether or not it is legal for a pharmacist to transfer a prescription for durable medical equipment, such as insulin infusion sets, to a DME Supplier which would not have a pharmacist present after it has been filled and dispensed by the Pharmacy. Jim Bracewell made a motion to direct staff to respond by stating it appears a new prescription order would need to be obtained from the physician. Bill Prather seconded and the Board voted unanimously in favor of the motion.

Correspondence from Meredith Herndon, Wellstar Kennestone Regional Medical Center

The Board considered this correspondence regarding MTM service in an inpatient setting. Jim Bracewell made a motion to direct staff to respond by stating if they wanted to do MTM services, the Board has no objections to the questions proposed. Laird Miller seconded and the Board voted unanimously in favor of the motion.

Correspondence from Mark Matheson

The Board considered this correspondence regarding script count versus pharmacist hours. The Board directed staff to respond to Mr. Matheson by thanking him for his correspondence and advising that this matter would take a change in state law.

Correspondence from Representative Sharon Cooper

The Board considered this correspondence regarding section (1) of Board Rule 480-7-.07 Credit for Returned Expired Drugs. Lisa Harris made a motion to direct staff to respond by stating the Board would like to express its appreciation to Representative Cooper for bringing this matter to its attention and will be working expeditiously to amend its rule to address the concern she has raised. Jim Bracewell seconded and the Board voted unanimously in favor of the motion.

Correspondence from Bendin, Sumrall & Ladner, LLC

The Board considered this correspondence regarding its public hearing held in July 2017 concerning notice of intent to adopt Rule 480-13-11 Required Notifications to the Board and Rule 480-15-.05 Duties or Functions Prohibited from Being Performed by a Registered Pharmacy Technician. Mr. Robert Stannard, who was present at the meeting, discussed alternative language to the proposed rules. President Jones thanked Mr. Stannard for his comments and advised that the Board will review the information submitted and will take it into consideration.

Correspondence from Debra Middleton Carr

The Board considered this correspondence regarding the use of an online prescription website to transfer prescriptions. Mike Faulk made a motion to direct staff to respond that based on the information provided, the practice proposed does not appear to be one that the Board would endorse. Lisa Harris seconded and the Board voted unanimously in favor of the motion.

Correspondence from Elizabeth Proctor, Compass Health

The Board considered this correspondence regarding regarding OTC and legend medical devices. Vicki Arnold made a motion to direct staff to respond by stating the Board does not require companies that only

ship non-prescription OTC drugs or Legend Medical Device Distributors to be licensed as wholesale distributors. Mike Faulk seconded and the Board voted unanimously in favor of the motion.

Georgia Drugs and Narcotics Agency – Dennis Troughton

President Jones welcomed Dennis Troughton as the new Director of Georgia Drugs and Narcotics Agency.

Attorney General's Report – Janet Wray

No report.

Executive Director's Report - Tanja Battle

Ms. Battle introduced Ms. Kimberly Emm, Attorney, to the Board.

Continuing Education Report: Report presented. Jim Bracewell made a motion to ratify the below named continuing education programs approved since the previous meeting.

Date of Program	Hours	Sponsoring Group	Program Title	CE Code	Date Notified
8/24/2017	0.5	Kaiser Permanente	Clinical Pharmacy Information Series	2017-0010	Approved 08/14/2017

Correspondence from Mike Long, Elements Behavioral Health: Ms. Battle reported that Mr. Long had previously presented information to the Board regarding two treatment facilities. Bill Prather made a motion to approve The Ranch of Mississippi and Promises Treatment Center as treatment facilities. Jim Bracewell seconded and the Board voted unanimously in favor of the motion.

2018 Meeting Dates: The Board recommended tabling this matter until its October 2017 meeting to allow additional time for review.

Ms. Battle discussed the Board's policy on public emergencies. Ms. Battle indicated there was an initial understanding that the policy would merely be implemented with each declaration of a State of Emergency. Ms. Wray and Ms. Battle confirmed that, while the policy does not speak to any one particular emergency, each time it is to be implemented for a specific event, it has to be forwarded to the Governor's Office for approval. This has been completed.

Miscellaneous

Rule 480-13-.05 Physical Requirements: At its July 2017 meeting, the Board requested to revisit this rule for a possible amendment regarding the requirement for a balance. President Jones asked for thoughts on this matter. After further discussion, the Board recommended not making any changes to the requirements at this time.

Mike Faulk made a motion to post Rule 480-13-.03 Personnel with the changes noted. Lisa Harris seconded and the Board voted unanimously in favor of the motion.

Rule 480-13-.03 Personnel.

(1) Director of Pharmacy. Each hospital pharmacy shall be directed by a pharmacist, hereinafter referred to as the Director of Pharmacy, who is licensed to engage in the practice of pharmacy in this State, and who is knowledgeable in and thoroughly familiar with the specialized functions of hospital pharmacies. The Director of Pharmacy shall be responsible for all activities of the hospital pharmacy, and for meeting the requirements of the Georgia Pharmacy Laws and Rules and Regulations of the Board of Pharmacy.

The Director of Pharmacy or his/her pharmacist designee should be employed on a fulltime basis consistent with need.
(2) Supportive personnel. The Director of Pharmacy shall be assisted by a sufficient number of additional pharmacists~~,~~ and ancillary personnel as may be required to operate such pharmacy competently, safely, and to meet the needs of the patients of the hospital facility.
(a) The Director of Pharmacy shall insure that trained personnel shall be employed in the pharmacy. The Director of Pharmacy shall develop and implement written policies and procedures to specify the duties to be performed by such personnel. These policies and procedures shall, at a minimum, specify that such personnel are personally and directly supervised by a licensed pharmacist and that such personnel are not assigned duties which may be performed only by licensed pharmacists. The Director of Pharmacy shall be responsible for the implementation of the written policies and responsible to the Georgia State Board of Pharmacy for the activities of the pharmacy.
(b) Secretarial and clerical assistance and support shall be provided as required to assist with record keeping, report submission, and other administrative duties, provided such personnel do not perform any dispensing duties.
(c) Any licensed pharmacist performing pharmaceutical duties within the hospital shall operate and fall under the supervision of the Director of Pharmacy.
(3) Supervision. All of the activities and operations of each hospital pharmacy shall be personally and directly supervised by its Director of Pharmacy. All functions and activities of non-licensed pharmacy personnel shall be personally and directly supervised by an adequate number of licensed pharmacists to insure that all such functions and activities are performed competently, safely, and without risk of harm to patients. Personal supervision can only be accomplished by the physical presence of a licensed pharmacist in the hospital.

Mike Faulk made a motion to post Rule 480-7-.05 Reverse Distributors with the changes noted. Vicki Arnold seconded and the Board voted unanimously in favor of the motion.

Rule 480-7-.05 Reverse Distributors.
(1) Every firm, whether located inside or outside the State of Georgia, which receives drugs for destruction, return credit, or otherwise disposes of drugs received from a registrant located in the State of Georgia which holds a permit or license to dispense or possess drugs, shall be known as a Reverse Distributor or a Reverse Drug Distributor.
(2) In order or any Reverse Distributor, wherever located, to engage in the business of receiving drugs for destruction, return credit, or other disposal from a registrant located in Georgia, it must be licensed as a Reverse Distributor by the Georgia State Board of Pharmacy ("Board").
(3) The minimum information required by the Board in order to register a Reverse Distributor will be the same as required under Rule 480-7-.03(2).
(4) The minimum requirements for applications for registration as a Reverse Distributor with the Board will be the same as required under Rule 480-7-.03(3).
(5) Personnel: The licensed Reverse Distributor shall employ adequate personnel with the education and experience necessary to safely and lawfully engage in the process of receiving drugs for destruction, credit return, or other means of disposal. Each such person shall have a working knowledge of the requirements for the law and rules for handling such drugs.
(6) Violations:
(a) A license issued to a Reverse Distributor pursuant to this part ~~shall~~ may be subject to revocation or suspension upon conviction of the license holder of or an employee of a reverse distributor for violations related to federal, state or local laws and/or rules.
(b) Violation of any provisions of any applicable Board Rules shall be grounds for the suspension, revocation, or other sanctions of the permit issued hereunder.
(c) Any action taken on a license pursuant to this part shall be carried out pursuant to the Georgia Administrative Procedure Act, O.C.G.A. Title 50, Chapter 13.

(7) Minimum requirements for the storage and handling of prescription drugs and or the establishment and maintenance of prescription drug distribution records by Reverse Distributors. A Reverse Distributor shall follow the same requirements as listed under Board Rule 480-7-.03(7), except as follows:
(a) A Reverse Distributor does not have to maintain a separate quarantine area for storing drugs which are outdated, damaged, etc., as noted under Rule 480-7-.03;
(b) A Reverse Distributor does not have to maintain drugs under controlled temperature and humidity as required under Rule 480-7-.03;
(c) A Reverse Distributor does not have to ensure the condition of drugs that are received or shipped as required under Rule 480-7-.03(7)(d) or (e)~~.~~;
(d) ~~In addition to a Reverse Distributor having to follow all of the requirements of Rule 480-7-.03(7), p~~Prior to a Reverse Distributor removing ~~or receiving~~ drugs from a registrant, the Reverse Distributor must generate paperwork, a copy of which must be provided to and maintained by the registrant and a copy to be maintained by the Reverse Distributor, both for two (2) years, which at minimum records the following:
1. The date and time that the drugs left or were taken from the registrant;
2. A complete inventory of the drugs being transferred to the Reverse Distributor;
3. The name, Board permit number, address, and telephone number of the Reverse Distributor removing the drugs;
4. The name and signature of the responsible person representing the Reverse Distributor physically removing the drugs~~ or receiving the drugs~~; ~~and~~
5. The name and signature of the pharmacist representing a pharmacy~~,~~ or responsible person representing another type of registrant transferring the drugs to the Reverse Distributor and the name and principal address of the pharmacy or other registrant from which the drugs are removed; and
6. Any and all other information required under Ga. Comp. R. & Reg. c. 480-50 and applicable federal law and regulation.
(e) Upon a Reverse Distributor's receipt of drugs from a registrant by contract or common carrier, the Reverse Distributor must generate paperwork, a copy of which must be maintained by the Reverse Distributor for two (2) years, which at minimum records the following:
1. The date and time that the drugs were received by the Reverse Distributor;
2. A complete inventory of the drugs received by the Reverse Distributor;
3. The name and signature of the pharmacist representing a pharmacy or responsible person representing another type of registrant sending the drugs to the Reverse Distributor and the name and principal address of the pharmacy or other registrant from which the drugs are sent; and
4. Any and all other information required under Ga. Comp. R. & Reg. c. 480-50 and applicable federal law and regulation.

Lisa Harris made a motion to post Chapter 480-51 Interchangeable Biological Products with the changes noted. Vicki Arnold seconded and the Board voted unanimously in favor of the motion.

CHAPTER 480-51: INTERCHANGEABLE BIOLOGICAL PRODUCTS

480-51-.01 Definitions.

(1) "Biological product" means a biological product as defined in subsection (i) of section 351 of the Public Health Service Act, 42 U.S.C. Section 262.
(2) "Interchangeable biological product" means a biological product that the federal Food and Drug Administration has determined meets the standards set forth in subsection (k)(4) of 42 U.S.C. 262 or has been deemed therapeutically equivalent by the federal Food and Drug Administration.

480-51-.02 Substituting Interchangeable Biological Products.

(1) If a practitioner of the healing arts prescribes a biological product by its nonproprietary name, the pharmacist may substitute the biological product with an interchangeable biological product, but shall dispense the lowest retail-priced interchangeable biological product, which is in stock.

(2) Substitutions as provided in this rule are authorized for the express purpose of making available to the consumer the lowest retail priced interchangeable biological product which is in stock.

(3) Whenever a substitution is made:

(a) The pharmacist shall record on the original prescription the fact that there has been a substitution and the identity of the dispensed interchangeable biological product and its manufacturer. Such prescription shall be maintained for two years and shall be available for inspection by the board or its representative.

(b) The pharmacist shall affix to the prescription label or container or an auxiliary label, the name of the interchangeable biological product, with an explanation of "interchangeable biological product for (insert name of prescribed biological product)" or similar language to indicate substitution has occurred, unless the prescribing practitioner indicated that the name of the biological product may not appear upon the prescription label.

1. This labeling requirement does not apply to biological products dispensed for in-patient hospital services, to hospital-administered biological products for outpatients, or to biological products in specialty packaging for dosing purposes. This labeling requirement does apply to hospital retail pharmacies and to any biological products dispensed by a hospital for a patient's use or administration at home.

(4) The substitution of any biological product by a registered pharmacist pursuant to this rule section does not constitute the practice of medicine.

(5) A patient for whom a prescription biological product order is intended may instruct a pharmacist not to substitute an interchangeable biological product in lieu of a prescribed biological product.

(6) A practitioner of the healing arts may instruct the pharmacist not to substitute an interchangeable biological product in lieu of a prescribed biological product by including the words “brand necessary” in the body of the prescription.

(a) When a prescription is a hard copy biological product order, such indication of brand necessary must be in the practitioner’s own handwriting and shall not be printed, applied by rubber stamp, or any such similar means.

(b) When the prescription is an electronic prescription drug or biological product order, the words “brand necessary” are not required to be in the practitioner’s own handwriting and may be included on the prescription in any manner or by any method.

(c) When a practitioner has designated “brand necessary” on an electronic biological product order or interchangeable biological product shall not be substituted without the practitioner’s express consent, which shall be documented by the pharmacist on the prescription and by the practitioner in the patient’s medical record.

(7) Within forty-eight (48) hours, excluding weekends and holidays, following the dispensing of a biological product, the dispensing pharmacist or the pharmacist’s designee shall communicate to the prescriber the specific product provided to the patient, including the name of the biological product and the manufacturer.

(a) The communication shall be conveyed by making an entry into an interoperable electronic medical records system or through electronic prescribing technology or a pharmacy record that is electronically accessible by the prescriber. Otherwise, the pharmacist shall communicate the biological product dispensed to the prescriber by using facsimile, telephone, electronic transmission, or other prevailing means, provided that communication shall not be required where:

1. There is no interchangeable biological product approved by the federal Food and Drug Administration for the prescribed product; or

2. A refill prescription is not changed from the product dispensed on the prior filling of the prescription.

(8) A link for the current list of all biological products determined by the federal Food and Drug Administration to be interchangeable with a specific biological products is available on the Board’s website.

A motion was made by Laird Miller, seconded by Bill Prather, and the Board voted that the formulation and adoption of these rule amendments does not impose excessive regulatory cost on any licensee and any cost to comply with the proposed amendments cannot be reduced by a less expensive alternative that fully accomplishes the objectives of the relevant code sections.

In the same motion, the Board also voted that it is not legal or feasible to meet the objectives of the relevant code sections to adopt or implement differing actions for businesses as listed at O.C.G.A§ 50-13-4(a)(3)(A), (B), (C) and (D). The formulation and adoption of these rule amendments will impact every licensee in the same manner, and each licensee is independently licensed, owned and operated and dominant in the field of pharmacy.

The Board discussed the effective date for Rule 480-7B-.02 DME Supplier Licensing Requirements. Ms. Battle reminded the Board that applications for such will need to be made available in time for applicants to apply and be issued a license prior to the effective date. She stated that the Board would not be able to post the proposed rule changes today, but requested everyone be open to a conference call for such if the drafts were ready prior to the next Board meeting. She further added that most facilities renew in odd numbered years and because there are so many, she requested the renewal date for the DME Suppliers be on even years. She also requested when issuing in 2018 to push the renewal date out to 2020. After further discussion, the Board recommended the effective date by June 1, 2018.

The Board discussed proposed Rule 480-7B-.05 Retention of Records, Safety Standards, Security, and Operations. Ms. Wray stated that Teresa Tatum, DME, wants to speak to the Board regarding requiring background checks on everyone coming into the home. Ms. Wray stated it has to be something that either requires the applicant to submit a background check or requires the company to have background check material on all its employees ready for GDNA to inspect when it goes into a facility. Ms. Battle responded that the Board registers pharmacy technicians so it has information regarding those individuals. She stated that if the Board is talking about every person, these will not be the ones applying for the license, but instead would be employees of the supplier. Ms. Wray says the situation would be similar to employees of a daycare. She stated the daycare is licensed, but the daycare employees must be checked. The license is for the facility, but it says people going into patient homes have to have a background check. Director Troughton commented that criminal history can only be seen by certain people. Ms. Wray responded that those would have to be available for GDNA to do certain inspections. President Jones suggested the background information be maintained onsite and be made available to GDNA upon inspection.

Ms. Wray discussed continuing education. She stated the requirement is listed in the proposed rule, but it does not state how much continuing education. She stated O.C.G.A. 26-4-51 9(b)(4)(A) reads *"Ensuring that all personnel engaged in delivery, maintenance, and repair of durable medical equipment receives annual continuing education".*

After further discussion, President Jones asked Mr. Miller to work with Ms. Emm on the suggested language and to report back to the Board.

Bill Prather made a motion and Laird Miller seconded, and the Board voted to enter into **Executive Session** in accordance with O.C.G.A. § 43-1-19(h)(2) and §43-1-2(k) to deliberate and to receive information on applications, investigative reports and the Assistant Attorney General's report. Voting in favor of the motion were those present who included Vicki Arnold, Jim Bracewell, Mike Faulk, Lisa Harris, Chris Jones, Laird Miller and Bill Prather.

Executive Session

Appearances

- S.L.H.
- R.A.S.
- H.M.F.
- E.U.H.

Georgia Drugs and Narcotics Agency – Dennis Troughton

Director Troughton had questions for the Board regarding ongoing investigations and enforcement matters.

Requested and received legal guidance regarding Rule 480-7-.02(1)(g)(1).

Cognizant's Report – Chris Jones

- GDNA Case # T-32254
- GDNA Case # T-32251
- GDNA Case # B-32128
- GDNA Case # B-32162
- GDNA Case # B-32210
- GDNA Case # B-32264
- GDNA Case # A-32247
- GDNA Case # B-32236
- GDNA Case #A-32246

Attorney General's Report – Janet Wray

Ms. Wray discussed the following cases:

- B.R./D.S.I.G.
- N.A.
- M.C.P.C.R. and M.C.P.

Ms. Wray presented the following consent orders:

- M.K.A.
- K.M.P.
- C.Z.
- J.W.M.
- J.J.S.

Executive Director's Report – Tanja Battle

- K.T.F.
- N.C.B.P.

Applications

- O.D.B.
- E.D.C.
- M.L.A.
- B.E.K.
- C.C.B.
- G.A.R.

- M.L.P.
- S.L.B.
- T.D.H.
- L.E.H.
- K.I.O.
- A.A.A.
- K.M.C.
- R.M.B.
- S.R.M.
- C.D.C.
- C.D.C.
- C.L.
- M.R.U.
- G.P.
- E.R.
- V.D.S.A.

Correspondences/Requests

- B.H.I.
- D.C.A.P.
- E.S.
- M.P.
- M.I.H.S.
- U.S.C.I.
- W.P.N.
- B.R.I.S.
- E.P.C.
- C.V.S.P.
- G.R.
- K.A.
- A.K.P.
- J.N.C.
- A.E.M.
- C.H.F.
- P.T.M.
- A.A.O.A.
- N.I.H.S.N.C.P.
- U.H.
- C.P.I.
- M.C.H.
- E.H.S.
- J.W.
- R.B.T.

No votes were taken in Executive Session. President Jones declared the meeting back in Open Session.

Open Session

Laird Miller made a motion for the Board to take the following actions:

Appearances

• S.L.H.	Denied Reinstatement	Uphold denial
• R.A.S.	Request to discuss reinstatement	Refer to the Department of Law
• H.M.F.	Denied Reinstatement	Uphold denial
• E.U.H.	Request regarding construction of a separate hospital tower	Board directed staff to respond by stating that a separate pharmacy license would not be required for the satellite pharmacy; however, if the DEA requires the satellite pharmacy to obtain a separate DEA permit, a separate pharmacy license would need to be obtained.

Georgia Drugs and Narcotics Agency – Dennis Troughton

Director Troughton had questions for the Board regarding ongoing investigations and enforcement matters.

Requested and received legal guidance regarding Rule 480-7-.02(1)(g)(1).

Cognizant's Report – Chris Jones

- GDNA Case # T-32254 Accept Voluntary Surrender
- GDNA Case # T-32251 Schedule Investigative Interview
- GDNA Case # B-32128 Close case with no action
- GDNA Case # B-32162 Close case with no action
- GDNA Case # B-32210 Close case with no action
- GDNA Case # B-32264 Close case with no action
- GDNA Case # A-32247 Refer to the Department of Law
- GDNA Case # B-32236 Close case with letter of concern
- GDNA Case #A-32246 Refer to the Department of Law

Attorney General's Report – Janet Wray

Ms. Wray discussed the following cases:

- B.R./D.S.I.G. Rescind referral to the Department of Law and close case with no action. Application approved with letter of concern.
- N.A. Rescind referral to the Department of Law and close case with no action. Renew license with letter of concern.
- M.C.P.C.R. and M.C.P. Refer to the Department of Law

Ms. Wray presented the following consent orders:

- M.K.A. Private Consent Order accepted
- K.M.P. Private Consent Order accepted
- C.Z. Private Consent Order accepted
- J.W.M. Private Consent Order accepted
- J.J.S. Private Consent Order accepted

Executive Director's Report – Tanja Battle

- K.T.F. Records request Denied request

- N.C.B.P. Records request Denied request

Applications

- Olympia D. Benjamin Pharmacy Technician Approved for registration
- Errica D. Cochran Pharmacy Technician Approved for registration
- Mahogany L. Allen Pharmacy Technician Approved for registration
- Blaine E. Kelley Pharmacy Technician Approved renewal
- Camille C. Bell Pharmacy Technician Approved renewal
- Gerald A. Riggins Pharmacy Technician Approved renewal
- Meghann L. Parker Pharmacy Technician Approved renewal
- Sentina L. Bowens Pharmacy Technician Approved for registration
- Tamera D. Hughes Pharmacist Interns Approved application
- Lauren E. Hawkins Pharmacist Interns Approved application
- Keith I. Okolo Pharmacist Interns Approved application
- Ahlam A. Alghamdi Temporary Pharmacist Approved application
- K.M.C. Pharmacist Reciprocity Approved to sit for the exam
- Robert M. Bougard Nuclear Pharmacist Approved application
- S.R.M. Pharmacist Reinstatement Table pending receipt of additional information
- C.D.C. Manufacturing Pharmacy Denied application
- Cantrell Drug Company Wholesaler Pharmacy Approved renewal
- C.L. Manufacturing Pharmacy Refer to the Department of Law
- M.R.U. Wholesaler Pharmacy Refer to the Department of Law
- Geneva Pharmacy, LLC Non-Resident Pharmacy Approved application
- EntrustRx Non-Resident Pharmacy Approved renewal
- V.D.S.A. Hospital Pharmacy No action taken

Correspondences/Requests

- B.H.I. Notice of Discipline No action taken
- D.C.A.P. Notice of Discipline No action taken
- E.S. Notice of Discipline No action taken
- M.P. Notice of Discipline No action taken
- M.I.H.S. Notice of Discipline No action taken
- U.S.C.I. Notice of Discipline No action taken
- W.P.N. Notice of Discipline No action taken
- B.R.I.S. Notice of Discipline No action taken
- E.P.C. Notice of Discipline No action taken
- C.V.S.P. Notice of Discipline No action taken
- G.R. Notice of Discipline No action taken
- K.A. Notice of Discipline No action taken
- A.K.P. Request to terminate probation Approved request
- J.N.C. Request to terminate probation Schedule to meet with the Board
- A.E.M. Request to terminate probation Denied request
- C.H.F. Report of positive drug screen Revoke Technician Registration
- P.T.M. Request to accept CE Approved request
- A.A.O.A. Request to take MPJE a 4th time Approved request

• N.I.H.S.N.C.P.	Request for fee exemption	Approved request
• U.H.	Remote order entry policy	Table pending receipt of additional information
• C.P.I.	Medical malpractice report	Refer to GDNA for investigation
• M.C.H.	Remote order entry policy	Table pending receipt of additional information
• E.H.S.	Remote order entry policy	Table pending receipt of additional information
• J.W.	Request to be eligible for licensure by score transfer	Board directed staff to respond by stating the individual must first obtain licensure in home state and then apply for licensure by reciprocity
• R.B.T.	Request to take MPJE a 4th time	Approved request

Jim Bracewell seconded and the Board voted unanimously in favor of the motion.

There being no further business to discuss, the meeting was adjourned at 4:27 p.m.

The next meeting of the Georgia Board of Pharmacy is scheduled for Wednesday, October 11, 2017 at 9:00 a.m. at the Department of Community Health's office located at 2 Peachtree Street, N.W., 5th Floor, Atlanta, GA 30303.

Minutes recorded by Brandi Howell, Business Support Analyst I
Minutes edited by Tanja D. Battle, Executive Director